References
- Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. Journal of Clinical Psychiatry 2001; 62(Suppl. 27)27–34
- Rouillon F, Sorbara F. Schizophrenia and diabetes: Epidemiological data. European Psychiatry 2005; 20(Suppl. 4)S345–S348
- Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Canadian Journal of Psychiatry 1991; 36: 239–245
- Lambert, T, Chapman, LH, on behalf of the Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. The Medical Journal of Australia 2004; 181: 544–548.
- Paton C, Esop R, Young C, Taylor D. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatry Scandinavia 2004; 110: 299–305
- Cuffel, B. American Psychiatric Association's Institute on Psychiatric Services, 2007.
- Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibbin G. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death; 13-year follow-up of participants in the study of men born in 1913. British Medical Journal 1984; 288: 1401–1404
- Gerstein HC. Relationship of glucose and insulin levels to the risk of myocardial infarction: case control study. Journal of the American College of Cardiology 1999; 33: 612–619
- Braceland FJ, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. American Journal of Psychiatry 1946; 102: 108–111
- Taylor D, Young C, Esop R, Paton C, Walwyn R. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. British Journal of Psychiatry 2004; 185: 152–156
- Walter G, DeLaroche A, Soh N, Hunt G, Cleary M, Malhi G, Lambert T, Correll C, Rey J. Side effects of second generation antipsychotics: the experience, views and monitoring practices of Australian child psychiatrists. Australasian Psychiatry 2008; 16: 253–262